康泰生物：五联疫苗开启Ⅲ期临床试验并完成首例受试者入组

Group 1 - The core point of the article is that Kangtai Biological (300601.SZ) has announced the initiation of Phase III clinical trials for its pentavalent vaccine, developed by its wholly-owned subsidiary Minhai Biological [1] - The pentavalent vaccine is designed to prevent invasive infections caused by diphtheria, tetanus, whooping cough, poliomyelitis, and Haemophilus influenzae type b [1]